Given that PD-L1 expression in tumor tissue is an important biomarker that predicts clinical outcomes of the anti-PD-1/PD-L1 treatment [93], it is possible that tumors in EGFR-mutated NSCLC express low levels of PD-L1. Here, PDCD1 is linked to neoplasm.